Plant pests such as bacteria and fungi lead to significant yield losses in agriculture. In order to develop new strategies ...

Home > Press release: New insights into the immune response of ... A team headed by biologist Prof Jörg Kudla has identified important components and mechanisms of the molecular machinery that ...

Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the immune system attacks nerves. Learn about symptoms, ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biotech company with a market capitalization of $631 ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

SCIENCE: Trudeau Institute, Ampersand Biosciences producing tools for flu research with $1M grant SARANAC LAKE — Local research and biotechnology laboratories Trudeau Institute and Ampersand ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

A study highlights the effectiveness of Talimogene laherparepvec (TVEC) for basal cell carcinoma. The virus-based therapy ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...